Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of April 2018. The report discloses the termination of a Research and License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., originally dated March 30, 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate event regarding a license agreement.
Material Changes
- Agreement Termination: On March 18, 2018, the Company terminated the License Agreement with Yissum, effective May 18, 2018.
- Scope of License: The terminated agreement covered a U.S. patent and foreign counterparts for the nasal delivery of cannabinoids, excluding use with Tramadol.
- Development Status: No regulatory filings were made, and no development results were generated under the agreement prior to termination.
- Resolution: The parties agreed to a mutual release in connection with the termination.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or a discussion of general risks. The primary contingency addressed is the conclusion of the specific intellectual property arrangement with Yissum.
Investor Verification Checklist
- Confirm the effective date of the termination (May 18, 2018) and any potential financial implications not detailed in this summary.
- Verify if the mutual release includes any undisclosed financial settlements or obligations.
- Check subsequent filings for updates on the Company's pipeline, as no development results were generated under this specific agreement.
- Ensure the registrant name is correctly identified as Therapix Biosciences Ltd., as the input metadata referenced "Scisparc Ltd."